NCT06685939

Brief Summary

Main objective: This project intends to design a simulated RCT project and clinically relevant RCT study to target, selecting the study titled "Short-Term outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial (Short-term Outcomes of Laparoscopic versus Open Pancreaticoduodenectomy in Patients with Pancreatic Ductal Adenocarcinoma)", use the cases in the Pancreatic Cancer Special Disease Cohort Database, compare the differences in complications and short-term prognosis between patients with pancreatic cancer after laparoscopic and open pancreaticoduodenectomy, investigate the efficacy and safety of laparoscopic pancreaticoduodenectomy, and provide the basis and reference of real-world data for clinical relevant studies. Secondary objective: To predict the incidence of postoperative complications and short-term outcomes of pancreatic cancer patients by comparing the difference of complications and short-term prognosis between laparoscopic and open pancreaticoduodenectomy, and to improve the treatment power of patients scheduled for surgery and postoperative patients.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
220

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2020

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

November 10, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 13, 2024

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2025

Completed
Last Updated

November 13, 2024

Status Verified

November 1, 2024

Enrollment Period

3 years

First QC Date

November 10, 2024

Last Update Submit

November 11, 2024

Conditions

Keywords

pancreatic cancerLPDOPDcomplication

Outcome Measures

Primary Outcomes (2)

  • Overall survive

    from the day after surgery to 3 years

  • complication

    any possible symptoms caused by surgery

    during the days Postoperative up to 1 year

Study Arms (1)

OPD

The patients who received the OPD

Procedure: LPD

Interventions

LPDPROCEDURE

The patients who received the LPD

OPD

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients treated with LPD or OPD for pancreatic cancer in Huadong Hospital from 1,January 2020 to 31,December 2022

You may qualify if:

  • Age: 18 years old, with no gender limit;
  • Histologically confirmed or clinically diagnosed as pancreatic cancer by MDT (multidisciplinary team), without histopathological evidence;
  • Patients may receive LPD or OPD according to the MDT evaluation;
  • Patients understand and are willing to comply with the trial;
  • Signed written informed consent before patient enrollment;
  • Patients who meet the clinical guidelines for intent to treat.
  • Those who met each of the above criteria were included in the study.

You may not qualify if:

  • Patients with distant metastasis found before or during surgery, including peritoneal, liver, distant lymph node metastasis, and other organ involvement;
  • Patients who need pancreatic neck or pancreatic tail, total pancreatic resection or other palliative surgery;
  • Preoperative anesthesia ASA score of 4 points;
  • A history of other malignant tumors;
  • Pregnant or lactating women;
  • Patients with severe mental disorders;
  • MDT evaluates patients with vascular invasion and requiring vascular resection based on abdominal imaging data;
  • Patients who have participated in other clinical trials within 3 months. Those who meet any of the above criteria were not included in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Huadong Hospital

Shanghai, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Pathological tissue,blood

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Dean

Study Record Dates

First Submitted

November 10, 2024

First Posted

November 13, 2024

Study Start

January 1, 2020

Primary Completion

December 31, 2022

Study Completion

July 31, 2025

Last Updated

November 13, 2024

Record last verified: 2024-11

Locations